

NEWS

Contact:

Paul Oestreicher, Ph.D.
Oestreicher Communications LLC
TEL: 917-536-3523
paul.oestreicher@ocomms.com

FOR IMMEDIATE RELEASE
4 March 2013



Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California

Key Markets Herald National Platform for Personalized Health, Medical Decision-Support and Clinical Genomic Diagnostics

HARTFORD, CONNECTICUT – Genomas[®], a biomedical company delivering personalized medicine to modern clinical practice, has been awarded clinical laboratory licenses by authorities in three of the most populous States. The company's Laboratory of Personalized Health received licenses from the New York Department of Health (*Permanent Facility Identifier 8648*), the Florida Agency for Health Care Administration (*License # 800026696*), and the California Department of Public Health (*Lab ID # COS 00800405*).

Gualberto Rúaño, M.D., Ph.D., President of Genomas and Director of the Laboratory of Personalized Health (LPH) stated: "New York, Florida, and California are among the most demanding States in terms of laboratory technical expertise and business credentialing. Now we are determined to deploy our capabilities outside of Connecticut, and to bring our clinical pharmacogenetics services to the people of these States and the entire nation."

LPH was certified previously by the Centers for Medicare and Medicaid Services (CMS) under CLIA (*Clinical Laboratory Improvement Amendments, ID # 07D1036625*), and was licensed by the Connecticut Department of Public Health (*license # CL-0644*) in 2005. In 2012, Genomas had attained credentialing as a Medicare provider (*National Provider Identifier NPI # 1336325497*) and began providing services to clinicians and patients in Texas and Pennsylvania.

More than 500 clinicians and 5000 patients in Connecticut have already benefitted from the Genomas HILomet PhyzioType[®] System, which allows personalized management of drugs to treat mental illness, neurological disorders, diabetes, and heart disease. Clinicians access the information through the Personalized Health Portal, which is a secure web-based interface providing data on over 250 different medications. The clinical support extends to 130 neuro-psychiatric drugs (antidepressants, neuroleptics, anticonvulsants, anxiolytics, stimulants, analgesics, hypnotics) and 120 cardio-metabolic drugs (to treat hypertension, diabetes, angina, thrombosis, gastroesophageal reflux disease, erectile dysfunction, asthma).

In Connecticut, Genomas has established a successful distribution and customer support partnership with Clinical Laboratory Partners (CLP). James Fantus, President and CEO of CLP, and Vice President of Hartford Healthcare Corporation, commented: "It is a great satisfaction to witness a national platform developing through Genomas from Hartford Healthcare partnerships, which include Clinical Laboratory Partners, Hartford Hospital, Institute of Living, and Hospital of Central Connecticut. Genomas is leading Connecticut to national prominence in the clinical practice of personalized medicine."

ABOUT THE HILOMET PHYZIO TYPE SYSTEM

The HILOmet PhyzioType, based on Genomas clinical studies and case reports, offers interpretative guidance to assess the functional status of a patient's drug metabolism. The HILOmet PhyzioType System enables clinicians to select the drug with the least risk and superior efficacy based on data derived from the patient's own genome. Clinicians typically refer patients experiencing drug intolerance, side effects, treatment resistance or therapeutic failure to medications. Other clinical conditions for referral are patients being treated with combinations of medications or medical devices, special populations such as children, adolescents, the elderly and the infirm, and patients hospitalized or with multiple medical conditions. The assays are non-invasive and require only a blood sample or buccal cheek swab. The Genomas Laboratory of Personalized Health offers rapid turnaround of two business days. The HILOmet PhyzioType System and its underlying physiogenomics technology have been published in the renowned journals *Annals of Biomedical Engineering*, *Atherosclerosis*, *Biomarkers in Medicine*, *Clinica Chimica Acta*, *Clinics in Laboratory Medicine*, *Connecticut Medicine*, *Future Cardiology*, *Hospital Health Networks*, *Molecular Psychiatry*, *Muscle & Nerve*, *Personalized Medicine*, *Pharmacogenomics*, and *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. The intellectual property portfolio of Genomas encompasses three issued US patents, three patent applications, three registered trademarks, and a copyright on the company's clinical informatics system.

ABOUT THE PERSONALIZED HEALTH PORTAL

The Personalized Health Portal provides clinicians real-time access to interactive information for gene-guided prescription of 250 drugs widely used in medicine. It profiles 130 Neuro-Psychiatric Drugs (antidepressants, pain, antipsychotics, stimulants, addiction, anticonvulsants, neurodegenerative, anxiolytics, sleep) and 120 Cardio-Metabolic Drugs (hypertension, cholesterol, diabetes, gastric reflux, asthma, erectile dysfunction, angina, antithrombotics, heart failure). It provides a timesaving, user friendly, password protected, interactive web interface for decision support. It enables the following functions: (a) benchmarking of innate drug metabolism function for each patient with comparisons to the population using four quantitative indices, (b) drug interactions assessed via interactive display, (c) clinician-customized archive of patient reports, and (d) drug selections + dosing with objective results and evidence-based predictive analyses.

ABOUT GENOMAS

Genomas[®] is a biomedical company delivering personalized medicine to modern clinical practice. The company develops revolutionary PhyzioType[®] Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance. PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient. The company's clinical pharmacogenetic tests and consultation services are provided through its Laboratory of Personalized Health (LPH), an accredited and licensed high-complexity molecular diagnostic center and its Personalized Health Portal (PHP), a medical informatics interface for clinician decision support. Genomas is located on the campus of Hartford Hospital in downtown Hartford, Connecticut. Please visit www.genomas.com for more information.

###